Clostridium difficile infection (CDI) is an intestinal infection usually acquired in hospital settings, after antibiotic treatment. The clinical spectrum of CDI ranges from mild diarrhoea to severe life-threatening pseudomembranous colitis. In the recent years, an increased incidence of CDI has been reported in Europe and worldwide.
Starting 15 September 2011, ECDC will be coordinating the former EUVAC.NET network. It is a surveillance network covering measles, mumps, rubella, congenital rubella, pertussis and varicella EU Member States and three countries of the European Economic Area. Data will be hosted by the European Surveillance System (TESSy) at ECDC.
Patient transfer between hospitals and in particular between countries, is a risk factor for the spread of bacteria that are resistant to last-line antibiotics. More specifically, for highly resistant bacteria, like carbapenamase-producing Enterobacteriaceae (CPE), the risk is heightened when patients are transferred from, or have received previous medical care in areas with high rates of bacterial resistance. These are conclusions from a risk assessment produced by ECDC that evaluated the risk to the citizens of Europe, of the spread of CPE through patient transfer between healthcare facilities, with special emphasis on cross-border transfer.
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.
On 21 July 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued its opinion on the review of Pandemrix® and reports on narcolepsy. The CHMP recommended that in persons under 20 years of age Pandemrix® may only be used if the recommended seasonal trivalent influenza vaccine is not available and if immunisation against H1N1 is still needed (e.g. in persons at risk of the complications of infection).
ECDC has previously summarised information concerning the appearance of narcolepsy following the use of a specific pandemic vaccine (Pandemrix®) in children and adolescents in three European Countries.
This review outlines how increasing modalities of travel, such as aeromedical evacuation of civilians and of military personnel, medical tourism and any shared healthcare across countries, are risks for the transmission of multidrug-resistant organisms via the patient, from country to country.
The European Medicines Agency (EMA) was key in the Europe during the 2009 pandemic concerning the authorisation and the benefit – risk assessment of the novel pandemic vaccines.
In late March, 2011 ECDC reported that the Swedish Medical Product Agency published preliminary results from an on-going cohort study involving 5.3 million people, where 67% of children and adolescents and 51.0% of adults were vaccinated with Pandemrix.